Articles tagged with Drug Combinations
A clinical study using the CURATE.AI platform successfully treated a patient with metastatic castration-resistant prostate cancer, completely halting disease progression. The AI platform continuously optimised novel drug combination dosages to achieve a durable response, allowing the patient to resume an active lifestyle.
Analysis of Medicare Part D spending reveals $925 million difference between brand-name combo drugs and using generic components. Prescriber education and substitution policies can help reduce costs by promoting generic substitution.
Researchers at NUS have developed an AI technology platform that can quickly determine the most effective drug combination for a patient. The Quadratic Phenotypic Optimisation Platform (QPOP) uses small experimental data sets to identify effective drug combinations and personalized treatment options.
Researchers developed QPOP, a computational platform that identifies effective drug combinations against bortezomib-resistant MM. The platform successfully predicted dosages for combination therapies, leading to reduced tumor size and prolonged survival in mouse models.
A team of researchers developed an AI system called Decagon to predict potential side effects from drug combinations. By analyzing cellular machinery interactions and known associations between drugs and side effects, the system identified patterns and predicted previously unseen consequences.
A large-scale screening of antibiotic combinations has identified over 500 pairs that improve antibiotic effectiveness against multi-drug resistant bacteria. These pairings could help combat antibiotic resistance by selectively targeting harmful bacterial species, reducing the development of resistance and its transmission.
Researchers at EMBL screened over 1100 treatment conditions using a novel microfluidic device, discovering individualized cancer therapies for each patient. The device was tested on four patient biopsies, showing highly reproducible results and potential for personalized medicine.
Monash researchers have created a computer model that can predict which combination of drugs will be most effective in treating triple negative breast cancer. The model, developed using genetic and treatment data from hundreds of patients, reveals a previously unknown combination of two drugs that may be successful.
A new study found that combination CC+AZ therapy is safe and effective for patients with elevated estradiol or low testosterone/estradiol ratios. The treatment improves testosterone levels and reduces estradiol levels by lowering conversion of testosterone to estradiol.
Researchers at the University of Pennsylvania School of Medicine found that a two-drug combination of mifepristone and misoprostol can effectively complete miscarriages, reducing the need for surgical intervention. The study showed that 91.2% of women experienced gestational sac expulsion after receiving the treatment.
Researchers at the University of Minnesota Medical School discovered an unrecognized cyclic pathway structure within the folate biosynthesis pathway, allowing each drug to enhance the activity of the other. This new mechanism has the potential to open doors for identification of other synergistic drug combinations.
The evidence for India's top-selling diabetes drug combinations falls short of WHO standards, potentially putting patients at risk. Only one trial assessed the balance between pros and cons, while 18 were sponsored by multinational corporations or conducted by pharmaceutical companies.
Many epilepsy patients receive antiepileptic and non-epilepsy drugs that can interact, altering the effectiveness of one or both types of medications. The study found over 1 in 5 patients taking such combinations may experience reduced efficacy or increased toxicity.
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of bet hedging. Genetic variations in cancer lead to differences in drug response, making combination therapy more effective by boosting the likelihood that a patient will benefit from at least one drug.
Researchers demonstrate an engineering approach to combine four drugs and control parasitic worms, a major breakthrough in treating nematode infections. The technique, developed by Chih-Ming Ho, uses a feedback system to quickly identify potent drug combinations that are effective on a small-animal model organism.
Researchers at CHEO identified sedation medications and practices associated with the best clinical outcomes, making ketamine-alone a logical choice for providing procedural sedation to children. The study found that choice of sedation medication had the biggest impact on the incidence of adverse events.
Computer simulations show moxifloxacin kills bacteria more quickly and performs better when doses are missed, making it a superior option for tuberculosis treatment. The research also found that levofloxacin killed bacteria more quickly than gatifloxacin.
A clinical trial at the University of Cincinnati is investigating a drug combination therapy using sirolimus and resveratrol to induce disease remission in patients with lymphangioleiomyomatosis (LAM). The study aims to identify a regimen that will eliminate LAM cells, which currently only suppress growth.
Researchers at the University of Pennsylvania have discovered a unique combination of hormone-based drugs that can produce enhanced weight loss in obese animals. The study found that cycling through different drug therapies over a month led to greater body weight loss compared to single-drug treatments.
Currently available drugs may be used alone or in combination to treat infectious diseases, addressing a pressing need due to slow development of new therapies. Non-profit entities and private industry collaboration is crucial for discovering novel interventions to combat drug-resistant pathogens.
A phase III clinical trial showed that combining lesinurad with febuxostat was more effective at lowering blood urate levels than febuxostat alone. The combination group achieved target urate levels in significantly more patients over 12 months.
A new study by University of Florida researcher Kalyani Sonawane finds that fixed-dose combination therapy associated with lower follow-up doctor visits and hospitalizations. Patients on this therapy are more likely to continue taking their medication as directed, resulting in significant cost savings.
Scientists have created a library of 308 compounds to test drug combinations for new therapies. A study found a synergy between flutamide and phenprocoumon that efficiently killed prostate cancer cells, targeting the androgen receptor. The CLOUD library is ideal for discovering new applications for approved active ingredients.
A study published in Journal of General Internal Medicine found that fixed-dose combination pills work best to encourage patients with high blood pressure to stick to their prescribed anti-hypertensive medications. Patients on these combined pills were 9% more likely to be persistent in taking their medication, compared to those on sin...
Scientists found that models with only two variables work best in combining drugs, reducing the risk of overfitting. The algorithm can be used to optimize various types of drug combinations, including those with multiple biological molecules.
A small study found that cancer patients treated with chemotherapy combination ABVD had more non-growing eggs in their ovaries, increasing the possibility of future fertility. Researchers believe further research is needed to understand this phenomenon.
A combination of formoterol and budesonide found to be safe and effective in treating moderate to severe asthma, with a lower risk of exacerbations than single-therapy budesonide. The therapy showed no significant increase in serious adverse events, providing reassurance for healthcare providers.
Scientists developed a novel algorithm to predict synergistic antifungal drug combinations for treating drug-resistant fungal infections. The algorithm, NLLSS, integrates various information types and experimentally validated 7 out of 13 predicted combinations for Candida albicans, providing new treatment options.
A new study by bioengineers at Brigham and Women's Hospital demonstrates the effectiveness of combination therapies in eliminating cancer cells. By pairing chemotherapy drug docetaxel with a targeted PI3K inhibitor, researchers achieved greater tumor inhibition and eliminated evidence of resistance.
Researchers at UCLA and Shanghai Jiao Tong University have developed a new feedback system control technique to pinpoint the best possible drug-dose ratios for treating tuberculosis. This approach has identified promising combination treatments that can kill bacteria much faster than standard regimens, potentially shortening treatment ...
Scientists at Stanford University have revived an abandoned drug that shows promise in fighting two disease-causing viruses, dengue and VEEV. The drug works by boosting the human body's ability to resist viruses rather than directly targeting them.
A new study found that one in six older adults now regularly use potentially deadly combinations of prescription and over-the-counter medications and dietary supplements. The study identified 15 potentially life-threatening drug combinations, with nearly half involving nonprescription medications or supplements.
Researchers from Kumamoto University used a new analysis system to evaluate the effectiveness of antithrombotic drugs in preventing and curing diseases caused by blood clots. The T-TAS system was able to accurately measure blood clotting ability, enabling healthcare providers to make informed decisions about medication management.
A Georgetown University Medical Center researcher is leading a multi-institutional effort to investigate the causes of rising drug-resistant malaria parasites. The study aims to understand molecular mechanisms responsible for this increasing resistance and develop new therapies.
Researchers have discovered a new combination of drugs that may be effective against resistant, BRAF-mutant melanoma by targeting different signaling pathways. The combination showed synergistic effects in tumors resistant to BRAF inhibition.
Researchers found that the combination therapy improved progression-free survival across various sub-groups, including those with poor prognostic factors. The study also showed similar efficacy regardless of BRAF mutation status and disease stage.
A 10-week randomized trial showed significantly reduced measures of agitation in patients treated with dextromethorphan-quinidine, with an average 51% reduction compared to placebo. The combination medication was associated with a lower risk of adverse events and cognitive impairment.
Researchers at Johns Hopkins Medicine discovered a protein-signaling process that accelerates the work of the most frequently mutated gene in adult leukemia. A combination of two drugs targeting this process and the gene itself slowed leukemia cell growth in mice, suggesting potential for improved treatment outcomes.
Associate Professor Suetonia Palmer's study provides an evidence-based guide on safe and effective blood-pressure-lowering drugs for patients with kidney disease and diabetes. The research, published in the Lancet journal, compared hundreds of studies to identify the most effective treatments.
Researchers found that imperfect drug penetration can lead to spatial monotherapy and rapid evolution of multidrug resistance. To combat this, doctors should consider drug combinations that reach similar parts of the body, potentially leaving pockets without any drugs.
A study by Queen Mary University of London found that over two-thirds of anti-depressant/benzodiazepine FDC sales and more than a quarter of NSAID FDC sales were from unapproved formulations. The researchers urge the Indian government to overhaul its drug regulatory system to prioritize patient safety.
A patented technology called CIVO enables simultaneous testing of multiple cancer drugs in a patient's tumor, accurately predicting systemic response. This innovation has shown positive findings using multiple cancer drugs tested in xenografted mouse models and canine patients.
Researchers have developed a multifaceted approach to identify drug combinations that reverse HIV-1 latency. Several 2-drug combinations were found to be able to reactivate HIV-1 without triggering an inflammatory response, and a model was created to correlate changes in viral RNA with virus secretion from T cells.
A new platform developed by UCLA bioengineers uses nanotechnology-enhanced medications and AI-driven analysis to create safer and more effective treatments for drug-resistant tumors. The approach, called Feedback System Control.II, has been shown to outperform traditional combination therapies.
Researchers developed a 3D-printed carrier that retains its shape and integrity, delivering immunosuppressive drug cyclosporine A and cells for local and sustained release. The system overcomes existing delivery limitations, providing a promising solution for treating diseases requiring cell-based therapy.
A randomized clinical trial compared the safety and effectiveness of combination therapy with rifapentine and isoniazid to treatment only with isoniazid. The study found that combination therapy was as effective in preventing TB in children, with zero cases reported in the combination group compared to three in the isoniazid-only group.
Researchers have identified a potential universal therapeutic target for treating multiple infections, including Ebola, by targeting the GRP78 protein. The OSU-03012 (AR-12) and FDA-approved Phosphodiesterase 5 Inhibitors combination has shown promise in preventing viral replication, killing cancer cells, and reducing antibiotic-resist...
Researchers at Saint Louis University discover a family of enzyme inhibitors that can suppress herpes simplex virus replication. The findings offer hope for new treatments that can work in combination with existing medications to completely suppress the virus.
Researchers found that a combination of specialist behavioral support and medication significantly increases the odds of smoking cessation success, with a 23% quit rate among study participants. The approach outperformed unaided quitting and nicotine replacement therapy alone.
A two-year clinical trial found that long-term use of a drug combination reduces the risk of recurrent urinary tract infection by up to 80% in children with vesicoureteral reflux. Children with bladder and bowel dysfunction saw the greatest reduction, up to an 80% lower risk of recurrent infections.
A study found that combination therapy with varenicline and bupropion resulted in better smoking abstinence rates at 12 weeks compared to monotherapy, but not at one year. After one year, the rates were similar, indicating that combination therapy may not provide a significant long-term benefit for smoking cessation.
The UCSF Global Health Group will conduct research on community-based strategies to identify and clear the last remaining malaria parasites in areas close to elimination. The goal is to determine risk factors associated with malaria transmission and explore effective interventions for high-risk groups.
A new study at Columbia University's Mailman School of Public Health found that drivers who test positive for drugs are three times more likely to be involved in a fatal crash. The study also showed that the combination of alcohol and drugs increases the risk by 23 times, making drugged driving a critical safety issue.
Researchers at the University of Minnesota Academic Health Center have developed a new delivery system for a combination of two FDA-approved drugs that may serve as an effective treatment for HIV. The discovery allows for a pill-form combination of decitabine and gemcitabine, marking a major step forward in patient feasibility.
A combination of two FDA-approved osteoporosis drugs, denosumab and teriparatide, was found to increase bone density more effectively than single-drug therapy in a small clinical trial. The treatment produced significant improvements in bone mineral density at multiple measured sites, including the lumbar spine and hip.
Researchers at Dartmouth-Hitchcock's Norris Cotton Cancer Center have found an innovative drug combination that targets the stubborn CLL cells. The combination of gossypol and navitoclax has shown to be effective in killing CLL cells, offering a new hope for patients with this disease.
Researchers found that a Bortezomib/Vorinostat combination therapy reactivated virus-induced cell lysis and induced PEL cell death, increasing the lifespan of mice with PEL tumors. This treatment combination could potentially be beneficial for immunocompromised patients with KSHV-associated malignancies.
Phase I and II trials of combining drugs to treat melanoma, including dabrafenib and trametinib, demonstrate a clinically meaningful improvement in progression-free survival, response rate, and duration of response. These studies suggest the potential for new drug combinations to delay resistance to BRAF inhibitors.
A new study found that cooking with a blend of sesame and rice bran oils significantly lowers blood pressure and improves cholesterol levels. The researchers discovered that the oil blend works nearly as well as a commonly prescribed high blood pressure medication, with even more impressive results when used in combination.
A new collaboration between DNDi and Cipla aims to develop a 4-in-1 ARV combination product for young children with HIV/AIDS, addressing the gap in current treatments. The goal is to provide safe, potent, child-friendly treatment combinations to accelerate care provision for infants and toddlers living with HIV/AIDS.